|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties. |
| 公司地址
| 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237 |
| 電話號碼
| +1 720 437-6580 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.aytubio.com |
| 員工數量
| 83 |
| Mr. Greg Pyszczymuka |
Chief Commercial Officer |
美元 401.40K |
24/10/2025 |
| Mr. Jarrett T. Disbrow |
Chief Business Officer |
美元 386.25K |
24/10/2025 |
| Mr. Joshua R. Disbrow |
Director and Chief Executive Officer |
美元 590.00K |
24/10/2025 |
| Mr. Ryan J. Selhorn |
Chief Financial Officer, Principal Accounting Officer, Corporate Secretary and Treasurer |
美元 379.80K |
24/10/2025 |
|
|
| Mr. Joshua R. Disbrow |
Director and Chief Executive Officer |
24/10/2025 |
| Mr. Carl C. Dockery |
Independent Director |
24/10/2025 |
| Mr. John A. Donofrio, Jr |
Chairman of the Board |
24/10/2025 |
| Mr. Abhinav Jain |
Independent Director |
24/10/2025 |
| Ms. Vivian H. Liu |
Independent Director |
24/10/2025 |
|
|
|
|
